DAVID SCOTT PEABODY
General Contractor at Eubank, Albuquerque, NM
License number
New Mexico 375025
Issued Date
Jul 9, 2012
Category
Contractor
Address
Address
1529 Eubank Blvd NE SUITE F, Albuquerque, NM 87112
Phone
(505) 292-4444
Professional information
Owner, Fastsigns
Position:
Owner at fastsigns
Location:
Albuquerque, New Mexico Area
Industry:
Printing
Work:
fastsigns
since Oct 2001
-
Owner
Education:
The University of New Mexico 1995 - 2000
Eldorado High school 1990 - 1994
Eldorado High school 1990 - 1994
Skills:
Digital Printing, Wide Format Printing, Logo Design, Signs, Vehicle Graphics, Decals, Vehicle Lettering, Banners
Owner At Fastsigns Ne Heights
Position:
Owner at FastSigns NE Heights
Location:
Albuquerque, New Mexico Area
Industry:
Graphic Design
Work:
FastSigns NE Heights
since Jul 2005
-
Owner
Immunogenic Respiratory Syncytial Virus Glycoprotein-Containing Vlps And Related Compositions, Constructs, And Therapeutic Methods
US Patent:
2013030, Nov 14, 2013
Filed:
Sep 13, 2011
Appl. No.:
13/820891
Inventors:
Bryce C. Chackerian - Albuquerque NM, US
David S. Peabody - Albuquerque NM, US
David S. Peabody - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
International Classification:
A61K 39/155
US Classification:
4242111
Abstract:
The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.
Plasmids And Methods For Peptide Display And Affinity-Selection On Virus-Like Particles Of Rna Bacteriophages
US Patent:
2012029, Nov 22, 2012
Filed:
Dec 31, 2010
Appl. No.:
13/520057
Inventors:
David S. Peabody - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
International Classification:
C12N 15/70, C12N 7/00, C40B 40/02, C40B 30/04, C40B 30/00, C07K 2/00, C07K 1/14, C12N 1/21, C40B 50/06
US Classification:
506 9, 4353201, 43525233, 4352351, 506 14, 506 26, 506 7, 530344
Abstract:
The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on VLPs, especially MS2 VLPS over a wide range, from few than one-on average—to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of MS2 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates MS2 niRNA. Nucleic acid constructs are also disclosed which are useful in the expression of virus-like particles comprised of a coat polypeptide of PP7 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates PP7 mRNA.
Immunogenic Hpv L2-Containing Vlps And Related Compositions, Constructs, And Therapeutic Methods
US Patent:
2012030, Dec 6, 2012
Filed:
Feb 8, 2011
Appl. No.:
13/577484
Inventors:
Bryce Chackerian - Albuquerque NM, US
David S. Peabody - Albuquerque NM, US
David S. Peabody - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
International Classification:
A61K 39/12, C12N 15/63, A61P 31/20
US Classification:
4241861, 4242041, 4353201
Abstract:
The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.
Methods For Screening Viral Like Particles And Identifying Neutralizing Epitopes And Related Vaccines, Constructs, And Libraries
US Patent:
2013014, Jun 13, 2013
Filed:
Oct 26, 2012
Appl. No.:
13/662060
Inventors:
Brian L. Hjelle - Placitas NM, US
David S. Peabody - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
David S. Peabody - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
International Classification:
G01N 33/68
US Classification:
4242041, 506 2, 435 5, 536 2372
Abstract:
The invention is directed to methods of screening immunogenic viral like particles and related immunogenic compositions and diagnostic techniques. In one embodiment, the invention provides methods of screening immunogenic viral like particles containing peptides corresponding to epitope regions of a wide variety of pathogens, including viruses, bacteria, parasites, and microbes. Non-infectious antigens and allergens of interest can also be screened as described herein. Immunization, therapeutic and diagnostic applications are also described for the compositions and methods according to the invention.In another embodiment, the invention provides novel methods of identifying a cryptic neutralizing epitope and related vaccines, constructs, and libraries. In some embodiments, these methods use high-throughput formats that are facilitated by in silica or in vitro steps.
Virus-Like Platform For Rapid Vaccine Discovery
US Patent:
2009005, Feb 26, 2009
Filed:
Aug 23, 2007
Appl. No.:
11/895198
Inventors:
David S. Peabody - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
International Classification:
C40B 30/00, C40B 40/10, C07H 21/04, C07K 1/00, C40B 50/06
US Classification:
506 7, 506 18, 536 2372, 506 26, 530412, 530413
Abstract:
The invention is directed to virus-like particles (VLPs) of an RNA bacteriophage that (a) comprises a coat polypeptide of said phage modified by insertion of a heterologous peptide that is displayed on said VLP and (b) encapsidates said bacteriophage mRNA as well as populations of these VLPs, and their uses. The invention is further directed to VLPs that encapsidate heterologous substances, as well as populations of these VLPs and their uses.
Virus-Like Platform For Rapid Vaccine Discovery
US Patent:
2011010, May 5, 2011
Filed:
Nov 10, 2010
Appl. No.:
12/943709
Inventors:
David S. PEABODY - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
International Classification:
A61K 39/21, C07H 21/04, C40B 50/06, C40B 30/00, C12P 21/00, A61K 39/12, A61P 31/18, A61P 31/12
US Classification:
4242081, 536 2372, 506 26, 506 7, 435 693, 4242041
Abstract:
The invention is directed to virus-like particles (VLPs) of an RNA bacteriophage that (a) comprises a coat polypeptide of said phage modified by insertion of a heterologous peptide that is displayed on said VLP and (b) encapsidates said bacteriophage mRNA as well as populations of these VLPs, and their uses. The invention is further directed to VLPs that encapsidate heterologous substances, as well as populations of these VLPs and their uses.
Display Of Antibody Fragments On Virus-Like Particles Of Rna Bacteriophages
US Patent:
2013001, Jan 17, 2013
Filed:
Mar 17, 2011
Appl. No.:
13/583047
Inventors:
David S. Peabody - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
Bryce Chackerian - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
International Classification:
A61K 39/395, A61P 31/12, A61P 35/02, C12N 1/21, C12N 15/63, C12N 15/11, C40B 50/06, C40B 30/04, A61P 35/00, G01N 33/574
US Classification:
4241781, 435 723, 4353201, 536 231, 506 26, 506 9, 43525233, 43525234
Abstract:
The invention enables the display of antibody single-chain variable fragments (scFv's on virus-like particles (VLPs) of bacteriophages such as MS2. The VLPs encapsidate mRNA encoding the coat protein from which it assembles, enabling the recovery by reverse transcription and PGR of affinity-selected sequences from scFv libraries. Related virus-like particles, method for constructing a library of scFv-VLPs, drug delivery vehicles comprising one or more pharmaceutically-active ingredients, biomedical imaging agents, assays, and kits are also provided.